Pharma Innovation Programme Singapore (PIPS)

 

The Pharma Innovation Programme Singapore (PIPS) is an industry-led platform which aims to synergistically and strategically bring together public sector research capabilities and domain expertise of the pharmaceutical industry to enhance the productivity and operational efficiency within Singapore’s pharmaceutical sector through leveraging novel manufacturing technologies and data analytics.

CARES has one ongoing collaboration with PIPS funded by Pfizer.

 

Digital Workflow and Continuous Processing in Pharmaceuticals Manufacturing

With funding from Pfizer as part of PIPS

Digital Workflow and Continuous Processing in Pharmaceuticals Manufacturing is led by Professor Alexei Lapkin. This is a two-year project which commenced in January 2021.

Project summary: Transformation of manufacturing in the pharmaceutical industry to new emerging business models (on demand, customisation, sustainable manufacturing, etc.) is heavily dependent on the development of supporting technologies, such as a novel manufacturing paradigm of fully continuous processes and digital tools for support of R&D and manufacturing. A number of current challenges in the supporting technologies are interlinked. Thus, development of effective flow processes and the use of continuous flow technology in manufacturing requires innovation in process modelling, reactor technology/reactor manufacturing, process data monitoring and knowledge management. This requirement spans the areas of synthesis, process engineering, process control, data science and artificial intelligence.

 

Completed PIPS projects are listed together with our other completed projects on this page.